Other

Restricted cash equivalents included in Other long-term assets

Boston Scientific Restricted cash equivalents included in Other long-term assets increased by 5.1% to $103.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 32.1%, from $78.00M to $103.00M. Over 4 years (FY 2020 to FY 2024), Restricted cash equivalents included in Other long-term assets shows an upward trend with a 11.4% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ3 2017
Last reportedQ3 2025
Metric ID: other_restricted_cash_equivalents_noncurrent

Historical Data

18 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Value$57.00M$57.00M$55.00M$59.00M$50.00M$48.00M$48.00M$57.00M$60.00M$58.00M$60.00M$74.00M$74.00M$78.00M$80.00M$91.00M$98.00M$103.00M
QoQ Change—+0.0%-3.5%+7.3%-15.3%-4.0%+0.0%+18.8%+5.3%-3.3%+3.4%+23.3%+0.0%+5.4%+2.6%+13.8%+7.7%+5.1%
YoY Change————-12.3%-15.8%-12.7%-3.4%+20.0%+20.8%+25.0%+29.8%+23.3%+34.5%+33.3%+23.0%+32.4%+32.1%
Range$48.00M – $103.00M
CAGR+14.9%
Avg YoY Growth+16.4%
Median YoY Growth+23.2%
Current Streak8 quarters growth

Frequently Asked Questions

What is Boston Scientific's restricted cash equivalents included in other long-term assets?
Boston Scientific (BSX) reported restricted cash equivalents included in other long-term assets of $103.00M in Q3 2025.
How has Boston Scientific's restricted cash equivalents included in other long-term assets changed year-over-year?
Boston Scientific's restricted cash equivalents included in other long-term assets increased by 32.1% year-over-year, from $78.00M to $103.00M.
What is the long-term trend for Boston Scientific's restricted cash equivalents included in other long-term assets?
Over 4 years (2020 to 2024), Boston Scientific's restricted cash equivalents included in other long-term assets has grown at a 11.4% compound annual growth rate (CAGR), from $52.00M to $80.00M.